Switch theme
Sign up to access all valuation multiples
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
2006
824
LTM Revenue $465M
LTM EBITDA $99.5M
$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Veracyte has a last 12-month revenue (LTM) of $465M and a last 12-month EBITDA of $99.5M.
In the most recent fiscal year, Veracyte achieved revenue of $446M and an EBITDA of $49.2M.
Veracyte expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Veracyte valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $465M | XXX | $446M | XXX | XXX | XXX |
| Gross Profit | $321M | XXX | $298M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $99.5M | XXX | $49.2M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 11% | XXX | XXX | XXX |
| EBIT | $24.9M | XXX | $20.0M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $31.7M | XXX | $24.1M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Veracyte's stock price is $27.
Veracyte has current market cap of $2.1B, and EV of $1.8B.
See Veracyte trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.8B | $2.1B | XXX | XXX | XXX | XXX | $0.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Veracyte has market cap of $2.1B and EV of $1.8B.
Veracyte's trades at 4.1x EV/Revenue multiple, and 37.5x EV/EBITDA.
Equity research analysts estimate Veracyte's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Veracyte has a P/E ratio of 65.7x.
See valuation multiples for Veracyte and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | 18.6x | XXX | 37.5x | XXX | XXX | XXX |
| EV/EBIT | 74.2x | XXX | 92.3x | XXX | XXX | XXX |
| EV/Gross Profit | 5.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 65.7x | XXX | 86.3x | XXX | XXX | XXX |
| EV/FCF | 20.8x | XXX | 28.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVeracyte's last 12 month revenue growth is 10%
Veracyte's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Veracyte's rule of 40 is -4% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Veracyte's rule of X is 47% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Veracyte and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -4% | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 47% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 62% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Veracyte acquired XXX companies to date.
Last acquisition by Veracyte was XXXXXXXX, XXXXX XXXXX XXXXXX . Veracyte acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Veracyte founded? | Veracyte was founded in 2006. |
| Where is Veracyte headquartered? | Veracyte is headquartered in United States of America. |
| How many employees does Veracyte have? | As of today, Veracyte has 824 employees. |
| Who is the CEO of Veracyte? | Veracyte's CEO is Mr. Marc A. Stapley. |
| Is Veracyte publicy listed? | Yes, Veracyte is a public company listed on NAS. |
| What is the stock symbol of Veracyte? | Veracyte trades under VCYT ticker. |
| When did Veracyte go public? | Veracyte went public in 2013. |
| Who are competitors of Veracyte? | Similar companies to Veracyte include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Veracyte? | Veracyte's current market cap is $2.1B |
| What is the current revenue of Veracyte? | Veracyte's last 12 months revenue is $465M. |
| What is the current revenue growth of Veracyte? | Veracyte revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Veracyte? | Current revenue multiple of Veracyte is 4.0x. |
| Is Veracyte profitable? | Yes, Veracyte is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Veracyte? | Veracyte's last 12 months EBITDA is $99.5M. |
| What is Veracyte's EBITDA margin? | Veracyte's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Veracyte? | Current EBITDA multiple of Veracyte is 18.6x. |
| What is the current FCF of Veracyte? | Veracyte's last 12 months FCF is $88.6M. |
| What is Veracyte's FCF margin? | Veracyte's last 12 months FCF margin is 19%. |
| What is the current EV/FCF multiple of Veracyte? | Current FCF multiple of Veracyte is 20.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
